Canaccord Genuity Sticks to Its Hold Rating for Smith & Nephew Snats (SNN)
Canaccord Genuity analyst Caitlin Roberts reiterated a Hold rating on Smith & Nephew Snats today and set a price target of $34.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Roberts is a 3-star analyst with an average return of 17.5% and a 61.54% success rate. Roberts covers the Healthcare sector, focusing on stocks such as Smith & Nephew Snats, Establishment Labs Holdings, and AxoGen.
The word on The Street in general, suggests a Hold analyst consensus rating for Smith & Nephew Snats with a $35.75 average price target.
Based on Smith & Nephew Snats’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $2.99 billion and a net profit of $295.65 million. In comparison, last year the company earned a revenue of $2.83 billion and had a net profit of $214 million
Read More on SNN:
Disclaimer & DisclosureReport an Issue
- Smith & Nephew: Strategic Integrity Orthopaedics Acquisition and Underappreciated Sports Medicine Growth Support Buy Rating
- Smith+Nephew to Acquire Integrity Orthopaedics to Bolster Shoulder Repair Portfolio
- Smith & Nephew’s PICO Venous Leg Ulcer Study Terminated: What Investors Should Know
- Smith & Nephew Updates Share Capital and Voting Rights as of Year-End 2025
- Smith & Nephew price target lowered to 1,482 GBp from 1,563 GBp at Morgan Stanley
